Company |
Clinical Program Title (Phase) |
Disease |
Advanced Cell Technology (ACTC) |
Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cells for Juvenile Macular Degeneration (Phase I/II) |
Juvenile Macular Degeneration |
Neuralstem, Inc (CUR) |
NSI-189 for Major Depression (Phase Ia) |
Major Depression |
Athersys (ATHX) |
MultiStem for Ulcerative Colitis (Phase II) |
Ulcerative Colitis |
Clinical Data (CLDA) |
Stedivaze for Cardiac Stress Testing (Phase III) |
Cardiac Stress Testing |
Aastrom (ASTM) |
Vascular Repair Cells for Peripheral Vascular Disease-related Critical Limb Ischemia (Phase IIb) |
Critical Limb Ischemia |
Xenoport (XNPT) |
Horizant for Restless Leg Syndrome (NDA) |
Restless Leg Syndrome |
Delcath (DCTH) |
Chemosaturation Therapy for Metastatic Melanoma in the Liver with Melphalan (NDA) |
Metastatic Melanoma in Liver |
Amarin (AMRN) |
AMR101 for High Triglycerides and on Statin Therapy (mixed dyslipidemia) (Phase III) |
High Triglycerides |
Advanced Cell Technology (ACTC) |
Myoblast Stem Cell Therapy for Heart Failure (Phase I) |
Heart Failure |
Amarin (AMRN) |
AMR101 for Very High Triglycerides (Phase III) |
Very High Triglycerides |